Abeona Therapeutics Inc【ABEO】株式ニュース

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

Form S-8 - Securities to be offered to employees in employee benefit plans

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CLEVELAND, , Dec. 31, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has...

Form 8-K - Current report

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CLEVELAND, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

FDA accepts BLA resubmission of pz-cel in recessive dystrophic epidermolysis bullosa and sets PDUFA target...

Form DEF 14A - Other definitive proxy statements

Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa

CLEVELAND, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the...

Abeona Therapeutics® Announces Participation in November Investor Conferences

CLEVELAND, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that...

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CLEVELAND, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has...

Form 8-K - Current report

Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration

CLEVELAND, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the...

barmarty 1週前

all this company has down in the last 3years is give their people raises and incentives and bonuses' if you are a long term investor all you get is stock reversals and b/s promises they are 1 step in front of the law. i hope their watching, if not i'll remind them

Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

👍️0

Monksdream 10月前

ABEO new 52+week high

👍️0

Monksdream 10月前

ABEO new 52 week high

👍️0

Monksdream 10月前

ABEO new 52 week high

👍️0

Monksdream 11月前

ABEO new 52 week high

👍️0

Monksdream 11月前

ABEO new 52 week high

👍️0

Monksdream 11月前

ABEO new 52 week high

👍️0

Joelzee 2年前

Of course this goes up after I close my position. ??

👍️0

Invest-in-America 2年前

You gots me CONFUSED, Young Lady!! YES, I indeed DID post over there --- which YOU should have IGNORED in the first place!! WHATEVER!!! Bottom line???? GO-GO-GO-BABL and HPCO!!! Those two are where I am 'losing-my-shirt' right now!!

👍️0

gail 2年前

you already posted there silly, so i replied to you there in pm. and yes, i know you cant pm back anymore.

👍️0

Invest-in-America 2年前

O.K., I'll take a look at THAT one right now.

👍️0

gail 2年前

i found it on my…

..

own but got back out, its junk, lol. i was replying to you on the other stock admp.

👍️0

Invest-in-America 2年前

ABEO: It's pronounced like, "ABALONE" (that Fish thing)!!

PS: I got your PM, but can't reply to it. Bottom line, do NOT "invest" in ANY of my stock picks!! (Which is great advice for ME, too!!)

👍️0

gail 2年前

can anyone pronounce …

..

this?

Abeona Therapeutics Announces Completion of Patient Follow-up in Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

👍️0

gail 2年前

nice pop in overnight trading. lets see what she does today.

👍️0

gail 2年前

quiet board but this stock is on the move! grabbed a few today.

👍️0

stock1ace1 2年前

$3.69 news data coming within a month

👍️0

stock1ace1 2年前

Topline data from the Phase 3 VIITAL™ study of EB-101 in RDEB is on track for late third quarter to early fourth quarter of 2022 upon completion of the last patient monitoring visit, which is expected by mid-September.

👍️0

stock1ace1 2年前

Buying $3.01 phase 3 data due anyday 3 mil o/s 3 mill float

Topline data from the Phase 3 VIITAL™ study of EB-101 in RDEB is on track for late third quarter to early fourth quarter of 2022 upon completion of the last patient monitoring visit, which is expected by mid-September.

👍️0

INFINITI 3年前

We need to get this over $1

* * $ABEO Video Chart 02-25-2021 * *

Link to Video - click here to watch the technical chart video

👍️0

jerseyboy 4年前

They are MBIO, SIOX, and GTHX. GTHX will be the most successful of the three, as they have a recently-approved drug that will change the face of the use of chemotherapy. It is still amazingly cheap relative to its value, and is an easy three-bagger within at most two years, and probably before that.

I had to say goodbye to Abeona earlier this week when its price rose above my basis, as I swore to myself that I would do so if it ever recovered from its rapid decline to $1.00. I split it among three other biopharmas which I think have more immediate prospects of bringing their pipelines to revenue-generating fruition. This is a good company, but I think bringing their pipeline to revenue-generating fruition will take awhile from this point. Michael Amoroso should get a lot of credit for what he's done so far as Abeona's leader. Good luck to all who invest here. You could find a lot worse companies in which to invest.

👍️0

jerseyboy 4年前

I like what they're doing and obviously also like the share price movement today. Michael Amoroso should get a lot of credit for the way he was able to turn this situation around.

👍️0

jerseyboy 4年前

Apparently from the news today Michael Amoroso does know what he is doing. I had a feeling that they were down but not out. I have a good feeling about the gradual and successful development of their pipeline.

The share price is certainly showing a nice steady increase.

👍️0

Golden Cross 4年前

Chart looks to be a nice steady incline here

👍️0

jerseyboy 4年前

With today's advance, this has almost doubled from the level to where it fell when the CEO and five directors simultaneously resigned. Hopefully the price advance reflects positive things that Michael Amoroso is doing to develop the company. I've held all my shares through the downturn, and have confidence in his background and the company's pipeline.

I feel like people are sleeping on this one. It was a major shock from which to recover to have the CEO and half of the board resign, but I think Michael Amoroso knows what he is doing and is doing a good job in moving the company forward, and I believe that there is good long-term potential here.

👍️0

railrider 4年前

News just out spiking up on it

👍️0

jerseyboy 4年前

Wow - nice jump today - up 17%! It's still a long way to my basis of $2.98 per share, but something is afoot here with the kind of volume we saw today.

👍️0

jerseyboy 4年前

Nice jump today and up over 50% from its low. Let's hope Michael Amoroso can do something here with the assets and the pipeline. He's certainly got the background to be able to bring it forward.

👍️0

ClayTrader 4年前

* * $ABEO Video Chart 11-11-2020 * *

Link to Video - click here to watch the technical chart video

👍️0

whytestocks 4年前

Breaking News: $ABEO What Are The Best Penny Stocks To Buy Now? 3 Biotech Stocks To Watch

3 Biotech Penny Stocks to Watch in 2020 Biotech penny stocks have become some of the most popular choices for all types of investors. Both institutional and retail investors have been working to seek gains in the biotech industry. Since the beginning of the year, investors have turn...

Got this from ABEO - What Are The Best Penny Stocks To Buy Now? 3 Biotech Stocks To Watch

👍️0

realfast95 4年前

2x813008 shares free options for 1 year, to two directors
WTF

👍️0

realfast95 4年前

On September 17, 2020, Abeona Therapeutics Inc. (the “Company”) had filed a Current Report on Form 8-K reporting that Steven H. Rouhandeh had notified the Company of his resignation from the Board of Directors (the “Board”), effective September 30, 2020. On September 30, 2020, Mr. Rouhandeh rescinded his resignation from the Board, and the Board accepted his rescission of resignation. Also on September 30, 2020, the Board voted unanimously to elect Mr. Rouhandeh as Chairman of the Board. Mr. Rouhandeh will not be taking on any additional compensation as Chairman other than what he was already receiving as a non-employee director, which such compensation is disclosed in the Company’s proxy statement filed on April 10, 2020.

8k

👍️0

whytestocks 4年前

BREAKING NEWS: $ABEO Abeona Therapeutics' Board of Directors Forms Special Committee to Oversee Operations, Develop Strategic Direction and Leadership Plan

Steven H. Rouhandeh Appointed as Chairman of the Board of Directors Jefferies LLC R etained as F inancial A dvisor to A ssist with the R eview of S trategic O ptions NEW YORK and CLEVELAND, Oct. 06, 2020 (GLOBE NEWSWI...

Find out more ABEO - Abeona Therapeutics' Board of Directors Forms Special Committee to Oversee Operations, Develop Strategic Direction and Leadership Plan

👍️0

realfast95 4年前

Steven Rouhandeh
Founder,Chairman and Chief Investment Officer at SCO Capital Partners
Location: United States

Mr. Steven H. Rouhandeh, also known as Steve, J.D., is the Founder of SCO Capital Partners, LLC and has been its Chairman and Chief Investment Officer since 1997. Mr. Rouhandeh is the Founder of SCO Financial Group, LLC and serves as its Chairman. He has been an Executive Chairman at PlasmaTech Biopharmaceuticals, Inc. since March 4, 2008 and has been its Principal Executive Officer since January 1, 2015.

👍️0

realfast95 4年前

Abeona Therapeutics’ Board of Directors Forms Special Committee to Oversee Operations, Develop Strategic Direction and Lead...
October 06 2020 - 04:01PM

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that its Board of Directors has formed a Special Committee to oversee and advise the executive leadership team on the operations of the Company, leveraging the respective medical, business development and financial expertise of its members. The Special Committee, which consists of current board members, is also working closely with the executive leadership team to develop the Company’s strategic direction and leadership plan as it continues to advance its clinical programs toward providing novel gene and cell therapies to patients who currently have no approved treatment options. The Company also announced the appointment of Steven H. Rouhandeh as Chairman of its Board of Directors.

Strategic Review

Abeona has retained Jefferies LLC as its financial advisor to assist with the review of strategic options focused on advancing the Company’s mission and maximizing stakeholder value. There can be no assurance this strategic review will result in the completion of any particular course of action. There is no defined timeline for completion of the review process and the Company does not intend to comment further unless a specific initiative is approved by the Board of Directors, the review process is concluded, or it is otherwise determined that other disclosure is appropriate.

👍️0

realfast95 4年前

Abeona Therapeutics selloff yesterday an overreaction, says B. Riley FBR 08:00 ABEO B. Riley FBR analyst Justin Zelin lowered the firm's price target on Abeona Therapeutics to $2 from $5 and reiterates a Buy rating on the shares. The company's assets, including manufacturing infrastructure, are worth more than the market's current valuation following yesterday's 41% selloff, Zelin tells investors in a research note. However, to reflect reduced transparency into Abeona's leadership and strategy Zelin lowered his probability of success for lead asset EB-101 from 65% to 50% and from 20% to 15% for AB-102 and AB-101. Nonetheless, the analyst views yesterday's pullback as overreaction and continues to see upside in the shares.

Read more at:
https://thefly.com/n.php?id=3167175

👍️0

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター